JeanMarie Guenot Improves the Medical Industry

Posted on February 22, 2017


JeanMarie Guenot is a business woman who majored in the field of medicine. She is well known to be in the pharmaceutical and biotechnology industry, as a result she has accomplished more than 20 years of experience in this field. She acquired a Ph.D. from the University of California as well as an MBA from the Wharton School from the University of Pennsylvania. She is also seen to construct or reconstruct other companies for the better future. These companies are mostly healing centers.


Dr JeanMarie Guenot started and managed SKS Ocular and SKS Ocular 1.the companies objective is to deliver drug technologies specifically, dry AMD and continuous release ocular medicine as well as ocular inflammation, therapeutics for glaucoma and macular degeneration. Before becoming a business advisor for Hoffmann-La Roche in Basel and Shanghai from the year 2008 to 2009, Dr. Guenot was a vice president of business and corporate Development at PDL BioPharma. She managed the Biogen Idec-PDL partial development and consisted of 3 distinctions of Phase 2 cancer also autoimmune illness medication patients.


The company earned $800 million deal. Later on Dr. Guenot was earned an award in BioBusiness Network’s Initiative in the year 2005. She also involved herself in the auction of PDL’s manufacturing and commercial businesses. She was a participant of the Executive Team and Portfolio Administration Committee of PDL. Her 20 years’ experience also includes oncology, autoimmune diseases, cardiovascular diseases, ophthalmic and neurology.

Amphivena Therapeutics is a company that is led by Dr. Guenot and her started in the year 2013 and is located in San Francisco, California. The duty of Amphivena is to eliminate all types of blood cancers and restore normal lives to people suffering from these diseases. They do this through an advanced therapy that connects the patient’s immune body to end tumor cells and their originators. Their mission is specifically to reestablish the cellular stability for a good blood establishment, circulation and role.


The company is initiating an antibody therapy that is the best bi-functional to report blood cancer signs with also high medical attention. The organization has collaborated with prominent companies and expertise as well as enough resources so as to develop a great network in developing the best therapy for patients.